Next-generation biopharmaceutical platform acquiring novel IP and developing novel molecular entities and enhanced drugs for oncology and pulmonary indications. Focus on inhaled therapeutics for invasive fungal infections with particle-engineered manufacturing and novel kinase inhibitors offering improved safety, efficacy, and tolerability for cancer patients.